指南与共识消化道出血炎症性肠病消化内镜

AGA临床实践更新:缺铁性贫血的管理专家综述

AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2024-06-12

本临床实践更新由AGA临床实践更新委员会委托并批准,基于文献综述和专家意见提出缺铁性贫血管理的最佳实践建议,因未进行系统评价,建议未对证据质量或推荐强度进行正式评级。内容涵盖口服铁剂选择与用法、静脉铁剂适应证与制剂选择、减重手术、炎症性肠病、门脉高压性胃病、胃窦血管扩张症、乳糜泻及小肠血管扩张症等情境下的管理建议。

要点

  • 口服铁剂无单一剂型优于其他剂型,硫酸亚铁因价格最低而首选。
  • 口服铁剂每日最多一次,隔日给药可能耐受性更好且吸收率与每日给药相似或相等。
  • 口服铁剂应加用维生素C以改善吸收。

核心结论

  • 本专家综述提出15条缺铁性贫血管理的最佳实践建议,涵盖口服铁剂、静脉铁剂及不同临床情境下的处理策略。
  • 因未进行系统评价,这些最佳实践建议不带有关于证据质量或推荐强度的正式评级。

研究设计与样本

  • 本专家综述由AGA临床实践更新委员会和AGA理事会委托并批准,经CPUC内部同行评议及《Clinical Gastroenterology and Hepatology》标准程序外部同行评议。
  • 最佳实践建议来自已发表文献综述和专家意见,未进行系统评价。

主要发现

  • 口服铁剂方面:无单一剂型优于其他剂型,硫酸亚铁因价格最低而首选;每日最多一次,隔日给药可能耐受性更好且吸收率与每日给药相似或相等;加用维生素C以改善吸收。
  • 静脉铁剂方面:口服铁剂不耐受、铁蛋白水平经口服铁剂试验无改善或口服铁剂不太可能被吸收时应使用静脉铁剂;能用1或2次输注替代铁缺乏的制剂优于需要超过2次输注的制剂;所有静脉铁剂风险相似,真正过敏反应非常罕见,绝大多数反应为补体激活相关假性过敏(输注反应),应按此处理。
  • 特殊情境:减重手术后、炎症性肠病伴活动性炎症且吸收受损、门脉高压性胃病伴持续出血且对口服铁剂无反应者应使用静脉铁剂;门脉高压性胃病无其他慢性失血来源者可考虑用非选择性β受体阻滞剂治疗门脉高压;胃窦血管扩张症对铁剂替代反应不足者可考虑内镜下套扎或氩离子凝固术等热疗;乳糜泻应确保无麸质饮食依从性,根据缺铁严重程度和耐受性考虑口服铁剂,铁储备无改善后改用静脉铁剂;疑似小肠出血血管扩张症行深部小肠镜时应使用远端附件,小肠血管扩张症可用氩离子凝固术等消融热疗或止血夹等机械方法治疗。

关键数值与推荐

  • 最佳实践建议1:无单一口服铁剂剂型优于其他剂型,硫酸亚铁因价格最低而首选。
  • 最佳实践建议2:口服铁剂每日最多一次,隔日给药可能耐受性更好且吸收率与每日给药相似或相等。
  • 最佳实践建议3:口服铁剂加用维生素C以改善吸收。
  • 最佳实践建议4:口服铁剂不耐受、铁蛋白水平经口服铁剂试验无改善或口服铁剂不太可能被吸收时,应使用静脉铁剂。
  • 最佳实践建议5:能用1或2次输注替代铁缺乏的静脉铁剂制剂优于需要超过2次输注的制剂。

临床怎么用

  • 口服铁剂首选硫酸亚铁,每日最多一次,可隔日给药,并加用维生素C。
  • 口服铁剂不耐受、铁蛋白无改善或口服铁剂不太可能被吸收时,使用静脉铁剂;优先选择1或2次输注即可替代铁缺乏的制剂。
  • 减重手术后、炎症性肠病伴活动性炎症且吸收受损、门脉高压性胃病伴持续出血且对口服铁剂无反应者,应使用静脉铁剂。
  • 门脉高压性胃病无其他慢性失血来源者,可考虑用非选择性β受体阻滞剂治疗门脉高压。
  • 胃窦血管扩张症对铁剂替代反应不足者,可考虑内镜下套扎或氩离子凝固术等热疗。

局限性

  • 因未进行系统评价,这些最佳实践建议不带有关于证据质量或推荐强度的正式评级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: In this Clinical Practice Update (CPU), we will Best Practice Advice (BPA) guidance on the appropriate management of iron deficiency anemia. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice (BPA) statements were drawn from a review of the published literature and from expert opinion. Since systematic reviews were not performed, these BPA statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE 1: No single formulation of oral iron has any advantages over any other. Ferrous sulfate is preferred as the least expensive iron formulation. BEST PRACTICE ADVICE 2: Give oral iron once a day at most. Every-other-day iron dosing may be better tolerated for some patients with similar or equal rates of iron absorption as daily dosing. BEST PRACTICE ADVICE 3: Add vitamin C to oral iron supplementation to improve absorption. BEST PRACTICE ADVICE 4: Intravenous iron should be used if the patient does not tolerate oral iron, ferritin levels do not improve with a trial of oral iron, or the patient has a condition in which oral iron is not likely to be absorbed. BEST PRACTICE ADVICE 5: Intravenous iron formulations that can replace iron deficits with 1 or 2 infusions are preferred over those that require more than 2 infusions. BEST PRACTICE ADVICE 6: All intravenous iron formulations have similar risks; true anaphylaxis is very rare. The vast majority of reactions to intravenous iron are complement activation-related pseudo-allergy (infusion reactions) and should be treated as such. BEST PRACTICE ADVICE 7: Intravenous iron therapy should be used in individuals who have undergone bariatric procedures, particularly those that are likely to disrupt normal duodenal iron absorption, and have iron-deficiency anemia with no identifiable source of chronic gastrointestinal blood loss. BEST PRACTICE ADVICE 8: In individuals with inflammatory bowel disease and iron-deficiency anemia, clinicians first should determine whether iron-deficiency anemia is owing to inadequate intake or absorption, or loss of iron, typically from gastrointestinal bleeding. Active inflammation should be treated effectively to enhance iron absorption or reduce iron depletion. BEST PRACTICE ADVICE 9: Intravenous iron therapy should be given in individuals with inflammatory bowel disease, iron-deficiency anemia, and active inflammation with compromised absorption. BEST PRACTICE ADVICE 10: In individuals with portal hypertensive gastropathy and iron-deficiency anemia, oral iron supplements initially should be used to replenish iron stores. Intravenous iron therapy should be used in patients with ongoing bleeding who do not respond to oral iron therapy. BEST PRACTICE ADVICE 11: In individuals with portal hypertensive gastropathy and iron-deficiency anemia without another identified source of chronic blood loss, treatment of portal hypertension with nonselective β-blockers can be considered. BEST PRACTICE ADVICE 12: In individuals with iron-deficiency anemia secondary to gastric antral vascular ectasia who have an inadequate response to iron replacement, consider endoscopic therapy with endoscopic band ligation or thermal methods such as argon plasma coagulation. BEST PRACTICE ADVICE 13: In patients with iron-deficiency anemia and celiac disease, ensure adherence to a gluten-free diet to improve iron absorption. Consider oral iron supplementation based on the severity of iron deficiency and patient tolerance, followed by intravenous iron therapy if iron stores do not improve. BEST PRACTICE ADVICE 14: Deep enteroscopy performed in patients with iron-deficiency anemia suspected to have small-bowel bleeding angioectasias should be performed with a distal attachment to improve detection and facilitate treatment. Small-bowel angioectasias may be treated with ablative thermal therapies such as argon plasma coagulation or with mechanical methods such as hemostatic clips. BEST PRACTICE ADVICE 15: Endoscopic treatment of angioectasias should be accompanied with iron replacement. Medical therapy for small-bowel angioectasias should be reserved for compassionate treatment in refractory cases when iron replacement and endoscopic therapy are ineffective.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. DeLoughery TG, Jackson CS, Ko CW, et al. AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review. Clin Gastroenterol Hepatol. 2024. PMID: 38864796. doi:10.1016/j.cgh.2024.03.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。